ZOGENIX INC (ZGNX) Stock Price, Quote, News and Overview
NASDAQ:ZGNX - Nasdaq - Common Stock
ZGNX Quote, Performance and Key Statistics
26.68
+0.42 (+1.6%)
The current stock price of ZGNX is 26.68 null. In the past month the price increased by 2.22%. In the past year, price increased by 28.64%.
ZGNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ZGNX
Company Profile
Zogenix, Inc. is a pharmaceutical company. The company is headquartered in Emeryville, California and currently employs 218 full-time employees. The company went IPO on 2010-11-23. The firm is engaged in the development and commercialization of therapies for rare diseases. The company is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The firm also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
Company Info
ZOGENIX INC
5959 Horton St Ste 500
Emeryville CALIFORNIA 94608 US
CEO: Stephen J. Farr
Employees: 218
Company Website: http://www.zogenix.com/
Phone: 15105508300.0
ZOGENIX INC / ZGNX FAQ
What is the stock price of ZOGENIX INC today?
The current stock price of ZGNX is 26.68 null. The price increased by 1.6% in the last trading session.
What is the ticker symbol for ZOGENIX INC stock?
The exchange symbol of ZOGENIX INC is ZGNX and it is listed on the Nasdaq exchange.
On which exchange is ZGNX stock listed?
ZGNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZOGENIX INC stock?
15 analysts have analysed ZGNX and the average price target is 37.3 null. This implies a price increase of 39.82% is expected in the next year compared to the current price of 26.68. Check the ZOGENIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZOGENIX INC worth?
ZOGENIX INC (ZGNX) has a market capitalization of 1.49B null. This makes ZGNX a Small Cap stock.
How many employees does ZOGENIX INC have?
ZOGENIX INC (ZGNX) currently has 218 employees.
What are the support and resistance levels for ZOGENIX INC (ZGNX) stock?
ZOGENIX INC (ZGNX) has a support level at 26.26 and a resistance level at 26.69. Check the full technical report for a detailed analysis of ZGNX support and resistance levels.
Is ZOGENIX INC (ZGNX) expected to grow?
The Revenue of ZOGENIX INC (ZGNX) is expected to grow by 113.18% in the next year. Check the estimates tab for more information on the ZGNX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZOGENIX INC (ZGNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZGNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZGNX, evaluating the profitability, health, valuation and growth aspects
- ZOGENIX INC (ZGNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZOGENIX INC (ZGNX) Sales and EPS estimates to see what analysts future expectations are.
- ZOGENIX INC (ZGNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZOGENIX INC (ZGNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZOGENIX INC (ZGNX) Stock Chart to make your own analysis
- ZOGENIX INC (ZGNX) Latest news and press-releases to stay up to date.
Does ZOGENIX INC (ZGNX) stock pay dividends?
ZGNX does not pay a dividend.
When does ZOGENIX INC (ZGNX) report earnings?
ZOGENIX INC (ZGNX) will report earnings on 2022-05-04.
What is the Price/Earnings (PE) ratio of ZOGENIX INC (ZGNX)?
ZOGENIX INC (ZGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.07).
ZGNX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZGNX. When comparing the yearly performance of all stocks, ZGNX is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
ZGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZGNX. ZGNX has a bad profitability rating. Also its financial health evaluation is rather negative.
ZGNX Financial Highlights
Over the last trailing twelve months ZGNX reported a non-GAAP Earnings per Share(EPS) of -4.07. The EPS decreased by -5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -278.4% | ||
| ROA | -48.54% | ||
| ROE | N/A | ||
| Debt/Equity | 0.88 |
ZGNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to ZGNX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 26.75% and a revenue growth 113.18% for ZGNX